At a glance
- Originator Aventis
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Excitatory amino acid antagonists; Glycine antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 06 Oct 1998 No-Development-Reported for Epilepsy in USA (Unknown route)
- 18 Jun 1996 Preclinical development for Epilepsy in USA (Unknown route)